Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation

Mostrar otras versiones (1)

As a part of our project aimed at developing new safe chemotherapeutic and chemoprophylactic agents against tropical diseases, fluorine-containing drugs structurally related to 4-phenoxyphenoxyethyl thiocyanate (1) were designed, synthesized, and evaluated as antiproliferative agents against Trypano...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Liñares, G.G
Otros Autores: Gismondi, S., Codesido, N.O, Moreno, S.N.J, Docampo, R., Rodriguez, J.B
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 2007
Materias:
wc 9
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
Biblioteca Central Dr. Luis F. Leloir (FCEN) de Universidad de Buenos Aires
LEADER 09596caa a22013577a 4500
001 PAPER-6399
003 AR-BaUEN
005 20230518203605.0
008 190411s2007 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-34547916413 
024 7 |2 cas  |a atovaquone, 94015-53-9, 95233-18-4; fluorine, 7782-41-4; Fluorine, 7782-41-4; Thiocyanates 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a BMCLE 
100 1 |a Liñares, G.G. 
245 1 0 |a Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation 
260 |c 2007 
270 1 0 |m Rodriguez, J.B.; Departamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellon 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina; email: jbr@qo.fcen.uba.ar 
506 |2 openaire  |e Política editorial 
504 |a Urbina, J.A., Docampo, R., (2003) Trends Parasitol., 19, p. 495 
504 |a Moncayo, A., (1995) Geneva, p. 67 
504 |a Brener, Z., (1973) Annu Rev. Microbiol., 27, p. 347 
504 |a De Souza, W., (1984) Int. Rev. Cytol., 86, p. 197 
504 |a García Liñares, G., Ravaschino, E., Rodriguez, J.B., (2006) Curr. Med. Chem., 13, p. 335 
504 |a Galel, S.A., Kirchhoff, L.V., (1996) Transfusion, 36, p. 227 
504 |a Shulman, I.A., Appleman, M.D., Saxena, S., Hiti, A.L., Kirchhoff, L.V., (1997) Transfusion, 37, p. 727 
504 |a Levine, N.D., Corliss, J.O., Cox, F.E.G., Deroux, G., Grain, J., Honigberg, B.M., Leedale, G.F., Wallace, F.G., (1980) J. Protozool., 27, p. 37 
504 |a Fichera, M.E., Roos, D.S., (1997) Nature, 390, p. 407 
504 |a Marr, J.J., Docampo, R., (1986) Rev. Infect. Dis., 8, p. 884 
504 |a De Castro, S.L., (1993) Acta Tropica, 53, p. 83 
504 |a Harris, C., Salgo, M.P., Tanowitz, H.B., Wittner, M., (1988) J. Infect. Dis., 157, p. 14 
504 |a Montoya, J.G., Liesenfeld, O., (2004) Lancet, 363, p. 1965 
504 |a Rodriguez, J.B., (2001) Curr. Pharm. Des., 7, p. 1105 
504 |a Augustyns, K., Amssoms, K., Yamani, A., Rajan, P.K., Haemers, A., (2001) Curr. Pharm. Des., 7, p. 1117 
504 |a Cazzulo, J.J., Stoka, V., Turk, V., (2001) Curr. Pharm. Des., 7, p. 1143 
504 |a Docampo, R., (2001) Curr. Pharm. Des., 7, p. 1157 
504 |a Docampo, R., Moreno, S.N.J., (2001) Curr. Drug Targets Infect. Disord., 1, p. 51 
504 |a de Lederkremer, R.M., Bertello, L.E., (2001) Curr. Pharm. Des., 7, p. 1165 
504 |a Docampo, R., Schmuñis, G.A., (1997) Parasitol. Today, 13, p. 129 
504 |a Urbina, J.A., Payares, G., Molina, J., Sanoja, C., Liendo, A., Lazardi, K., Piras, M.M., Ryley, J.F., (1996) Science, 273, p. 969 
504 |a Urbina, J.A., Payares, G., Contreras, L.M., Liendo, A., Sanoja, C., Molina, J., Piras, M., Loebenberg, D., (1998) Antimicrob. Agents Chemother., 42, p. 1771 
504 |a Gonzalez-Cappa, S.M., Stoppani, A.O.M., (1981) Biochem. Parasitol., 3, p. 169 
504 |a Urbina, J.A., (1999) J. Mol. Med., 77, p. 332 
504 |a Urbina, J.A., Vivas, J., Visual, G., Contreras, L.M., (1995) Mol. Biochem. Parasitol., 73, p. 199 
504 |a Molina, J., Brener, Z., Romanha, A.J., Urbina, J.A., (2000) J. Antimicrob. Chemother., 46, p. 137 
504 |a Cinque, G.M., Szajnman, S.H., Zhong, L., Docampo, R., Rodriguez, J.B., Gros, E.G., (1998) J. Med. Chem., 41, p. 1540 
504 |a Szajnman, S.H., Yan, W., Bailey, B.N., Docampo, R., Elhalem, E., Rodriguez, J.B., (2000) J. Med. Chem., 43, p. 1826 
504 |a Elhalem, E., Bailey, B.N., Docampo, R., Ujváry, I., Szajnman, S.H., Rodriguez, J.B., (2002) J. Med. Chem., 45, p. 3984 
504 |a Urbina, J.A., Concepcion, J.L., Montalvetti, A., Rodriguez, J.B., Docampo, R., (2003) Antimicrob. Agents Chemother., 47, p. 2047 
504 |a Dantas-Leite, L., Urbina, J.A., de Souza, W., Vommaro, R.C., (2004) Int. J. Antimicrob. Agents, 23, p. 620 
504 |a Dantas-Leite, L., Urbina, J.A., de Souza, W., Vommaro, R.C., (2005) Int. J. Antimicrob. Agents, 25, p. 130 
504 |a Martins-Duarte, E.S., Urbina, J.A., de Souza, W., Vommaro, R.C., (2006) J. Antimicrob. Chemother., 58, p. 59 
504 |a Schvartzapel, A.J., Zhong, L., Docampo, R., Rodriguez, J.B., Gros, E.G., (1997) J. Med. Chem., 40, p. 2314 
504 |a Chan, D.M.T., Monaco, K.L., Wang, R.-P., Winters, M.P., (1998) Tetrahedron Lett., 39, p. 2933 
504 |a Evans, D.A., Katz, J.L., West, T.R., (1998) Tetrahedron Lett., 39, p. 2937 
504 |a Lam, P.Y.S., Clark, C.G., Saubern, S., Adams, J., Winters, M.P., Chan, M.P.T., Combs, A., (1998) Tetrahedron Lett., 39, p. 2941 
504 |a note; note; Ravaschino, E.L., Docampo, R., Rodriguez, J.B., (2006) J. Med. Chem., 49, p. 426 
504 |a Yan, W., Moreno, S.N., (1998) J. Immunol. Methods, 220, p. 123 
504 |a note; note; Gubbels, M.-J., Striepen, B., (2003) Antimicrob. Agents Chemother., 47, p. 309 
520 3 |a As a part of our project aimed at developing new safe chemotherapeutic and chemoprophylactic agents against tropical diseases, fluorine-containing drugs structurally related to 4-phenoxyphenoxyethyl thiocyanate (1) were designed, synthesized, and evaluated as antiproliferative agents against Trypanosoma cruzi, the parasite responsible of American trypanosomiasis (Chagas' disease), and Toxoplasma gondii, the etiological agent of toxoplasmosis. This thiocyanate derivative had previously proven to be an effective agent against T. cruzi proliferation. Fluorine-containing thiocyanate derivatives 2 and 3 were threefold more potent than our lead drug 1 against intracellular T. cruzi. The biological evaluation against T. gondii was also very promising. The IC50 values corresponding to 2 and 3 were at the very low micromolar level against tachyzoites of T. gondii. Both of these drugs are interesting examples of effective antiparasitic agents that have outstanding potential not only as lead drugs but also to be used for further in vivo studies. © 2007 Elsevier Ltd. All rights reserved.  |l eng 
536 |a Detalles de la financiación: National Council for Scientific Research, PIP 5508 
536 |a Detalles de la financiación: Foundation for the National Institutes of Health, AI-68647, AI-68467 
536 |a Detalles de la financiación: Ellison Medical Foundation 
536 |a Detalles de la financiación: Universidad de Buenos Aires, X-252 
536 |a Detalles de la financiación: Agencia Nacional de Promoción Científica y Tecnológica, PICT2004 #21897 
536 |a Detalles de la financiación: We thank Cuing Jiang for technical help with the T. gondii assays. This work was supported by grants from the National Research Council of Argentina (PIP 5508), ANPCyT (PICT2004 #21897), and the Universidad de Buenos Aires (X-252) to J.B.R., and the U.S. National Institutes of Health to R.D. (AI-68647) and S.N.J.M. (AI-68467). G.G.L. thanks the Ellison Medical Foundation for a Fellowship. 
593 |a Departamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellon 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina 
593 |a Center for Tropical and Emerging Global Diseases, Department of Cellular Biology, University of Georgia, Athens, GA 30602, United States 
690 1 0 |a ARYLOXYETHYL THIOCYANATES 
690 1 0 |a CHAGAS' DISEASE 
690 1 0 |a SQUALENE SYNTHASE 
690 1 0 |a TOXOPLASMA GONDII 
690 1 0 |a TRYPANOSOMA CRUZI 
690 1 0 |a 4 PHENOXYPHENOXYETHYL THIOCYANATE 
690 1 0 |a ANTIPARASITIC AGENT 
690 1 0 |a ATOVAQUONE 
690 1 0 |a FLUORINE 
690 1 0 |a THIOCYANIC ACID DERIVATIVE 
690 1 0 |a UNCLASSIFIED DRUG 
690 1 0 |a WC 9 
690 1 0 |a ARTICLE 
690 1 0 |a CARBON NUCLEAR MAGNETIC RESONANCE 
690 1 0 |a CHAGAS DISEASE 
690 1 0 |a CHEMICAL REACTION 
690 1 0 |a DRUG EFFICACY 
690 1 0 |a DRUG STRUCTURE 
690 1 0 |a DRUG SYNTHESIS 
690 1 0 |a IC 50 
690 1 0 |a NONHUMAN 
690 1 0 |a PROTON NUCLEAR MAGNETIC RESONANCE 
690 1 0 |a TACHYZOITE 
690 1 0 |a TOXOPLASMA GONDII 
690 1 0 |a TOXOPLASMOSIS 
690 1 0 |a TRYPANOSOMA CRUZI 
690 1 0 |a ANIMALS 
690 1 0 |a DRUG DESIGN 
690 1 0 |a FLUORINE 
690 1 0 |a MAGNETIC RESONANCE SPECTROSCOPY 
690 1 0 |a THIOCYANATES 
690 1 0 |a TOXOPLASMA 
690 1 0 |a TRYPANOSOMA CRUZI 
690 1 0 |a TOXOPLASMA GONDII 
690 1 0 |a TRYPANOSOMA CRUZI 
653 0 0 |a wc 9 
700 1 |a Gismondi, S. 
700 1 |a Codesido, N.O. 
700 1 |a Moreno, S.N.J. 
700 1 |a Docampo, R. 
700 1 |a Rodriguez, J.B. 
773 0 |d 2007  |g v. 17  |h pp. 5068-5071  |k n. 18  |p Bioorg. Med. Chem. Lett.  |x 0960894X  |w (AR-BaUEN)CENRE-3990  |t Bioorganic and Medicinal Chemistry Letters 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547916413&doi=10.1016%2fj.bmcl.2007.07.012&partnerID=40&md5=29b0fe672e54960fee8c8e0c34b35c9c  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1016/j.bmcl.2007.07.012  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_0960894X_v17_n18_p5068_Linares  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0960894X_v17_n18_p5068_Linares  |y Registro en la Biblioteca Digital 
961 |a paper_0960894X_v17_n18_p5068_Linares  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 67352 

Ejemplares similares